These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 24075603)

  • 21. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial.
    Potkin SG; Cohen M; Panagides J
    J Clin Psychiatry; 2007 Oct; 68(10):1492-500. PubMed ID: 17960962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment.
    Kane JM; Mackle M; Snow-Adami L; Zhao J; Szegedi A; Panagides J
    J Clin Psychiatry; 2011 Mar; 72(3):349-55. PubMed ID: 21367356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.
    Feldman PD; Kaiser CJ; Kennedy JS; Sutton VK; Tran PV; Tollefson GD; Zhang F; Breier A
    J Clin Psychiatry; 2003 Sep; 64(9):998-1004. PubMed ID: 14628974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
    Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
    J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia.
    Dossenbach MR; Folnegovic-Smalc V; Hotujac L; Uglesic B; Tollefson GD; Grundy SL; Friedel P; Jakovljevic MM;
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):311-8. PubMed ID: 14751428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia.
    Dunayevich E; Buchanan RW; Chen CY; Yang J; Nilsen J; Dietrich JM; Sun H; Marder S
    Schizophr Res; 2017 Apr; 182():90-97. PubMed ID: 27789188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebo-controlled study.
    Kane JM; Yang R; Youakim JM
    Schizophr Res; 2012 Mar; 135(1-3):116-22. PubMed ID: 22178084
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone.
    Dossenbach MR; Kratky P; Schneidman M; Grundy SL; Metcalfe S; Tollefson GD; Belmaker RH
    J Clin Psychiatry; 2001; 62 Suppl 2():28-34. PubMed ID: 11232749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study.
    Kinoshita T; Bai YM; Kim JH; Miyake M; Oshima N
    Psychopharmacology (Berl); 2016 Jul; 233(14):2663-74. PubMed ID: 27271087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder.
    Stauffer VL; Sniadecki JL; Piezer KW; Gatz J; Kollack-Walker S; Hoffmann VP; Conley R; Durell T
    BMC Psychiatry; 2010 Nov; 10():89. PubMed ID: 21047395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.
    Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M
    J Clin Psychiatry; 2004 Apr; 65(4):551-6. PubMed ID: 15119920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meta-analyses of the efficacy of asenapine for acute schizophrenia: comparisons with placebo and other antipsychotics.
    Szegedi A; Verweij P; van Duijnhoven W; Mackle M; Cazorla P; Fennema H
    J Clin Psychiatry; 2012 Dec; 73(12):1533-40. PubMed ID: 23290326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of olanzapine and risperidone in schizophrenia: a randomized double-blind crossover design.
    Canive JM; Miller GA; Irwin JG; Moses SN; Thoma RJ; Edgar JC; Sherwood A; Torres F; Lanoue M; Lewis S; Hanlon FM; Weisend MP; Mead V; Tuason VB
    Psychopharmacol Bull; 2006; 39(1):105-16. PubMed ID: 17065975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.
    McEvoy JP; Lieberman JA; Perkins DO; Hamer RM; Gu H; Lazarus A; Sweitzer D; Olexy C; Weiden P; Strakowski SD
    Am J Psychiatry; 2007 Jul; 164(7):1050-60. PubMed ID: 17606657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial.
    Takahashi H; Kamata M; Yoshida K; Ishigooka J; Higuchi H
    J Clin Psychiatry; 2006 Oct; 67(10):1577-82. PubMed ID: 17107250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia.
    Shen JH; Zhao Y; Rosenzweig-Lipson S; Popp D; Williams JB; Giller E; Detke MJ; Kane JM
    J Psychiatr Res; 2014 Jun; 53():14-22. PubMed ID: 24613032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
    Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Asenapine.
    Weber J; McCormack PL
    CNS Drugs; 2009 Sep; 23(9):781-92. PubMed ID: 19689168
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension.
    Szegedi A; Calabrese JR; Stet L; Mackle M; Zhao J; Panagides J;
    J Clin Psychopharmacol; 2012 Feb; 32(1):46-55. PubMed ID: 22198448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.